Influence of Concurrent and Adjuvant Temozolomide on Health-Related Quality of Life of Patients with Grade III Gliomas: A Secondary Analysis of a Randomized Clinical Trial (KNOG-1101 Study)
Cancer Research and Treatment. 2022;54(2):396-405 
ACTR-50. EFFECT OF CONCURRENT AND ADJUVANT TEMOZOLOMIDE ON SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED GRADE III GLIOMAS WITHOUT 1p/19q CO-DELETION: A RANDOMIZED, OPEN-LABEL, PHASE 2 STUDY (INTERIM RESULTS FROM THE KNOG-1101 STUDY)
Neuro-Oncology. 2018;20(suppl_6):vi23-vi23
Concurrent and Adjuvant Temozolomide for Newly Diagnosed Grade III Gliomas without 1p/19q Co-deletion: A Randomized, Open-Label, Phase 2 Study (KNOG-1101 Study)
Cancer Research and Treatment. 2020;52(2):505-515
ACTR-14. A PROSPECTIVE RANDOMIZED STUDY OF CONCURRENT CHEMORADIOTHERAPY WITH TEMOZOLOMIDE VERSUS RADIOTHERAPY ALONE IN PATIENTS WITH IDH WILD-TYPE/TERT PROMOTER MUTATION GRADE II/III GLIOMAS
Neuro-Oncology. 2019;21(Supplement_6):vi15-vi15
SYST-10 CSNO2012001 STUDY: A PHASE III TRIAL ON ADJUVANT TEMOZOLOMIDE CHEMOTHERAPY WITH OR WITHOUT INTERFERON-ALPHA IN NEWLY DIAGNOSED HIGH-GRADE GLIOMAS
Neuro-Oncology Advances. 2022;4(Supplement_1):i23-i23
CTNI-33. CSNO2012001 STUDY: A PHASE III TRIAL ON ADJUVANT TEMOZOLOMIDE CHEMOTHERAPY WITH OR WITHOUT INTERFERON-ALPHA IN NEWLY DIAGNOSED HIGH-GRADE GLIOMAS
Neuro-Oncology. 2022;24(Supplement_7):vii78-vii78
Health-related quality of life aspects in patients with low-grade glioma
Low-Grade Gliomas. 2010;213-235
Health related quality of life improvement in chronic non-specific neck pain: secondary analysis from a single blinded, randomized clinical trial
Health and Quality of Life Outcomes. 2018;16(1):
Importance of evaluating health-related quality of life issues in survivors of WHO grade II or III gliomas
Neuro-Oncology Practice. 2022;9(1):1-2
Radiotherapy versus radiotherapy combined with temozolomide in high-risk low-grade gliomas after surgery:Study protocol for a randomized controlled clinical trial
. 2019;